Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian Wiestner

Showing results (71-80 of 182) with videos related to

Pageof 19
Sort By:
Blood|March 25, 2014
Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLLSarah E M Herman, Rashida Z Mustafa, Jennifer A Gyamfi, et al.
Blood|December 2, 2004
Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent mannerRuth Seggewiss, Karin Loré, Elisabeth Greiner, et al.
Haematologica|February 4, 2017
Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemiaMika Shapiro, Yair Herishanu, Ben-Zion Katz, et al.
Cancer Research|October 26, 2014
Harnessing the fcμ receptor for potent and selective cytotoxic therapy of chronic lymphocytic leukemiaBérengère Vire, Martin Skarzynski, Joshua D Thomas, et al.
Leukemia & Lymphoma|June 9, 2011
Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1Yair Herishanu, Federica Gibellini, Ndegwa Njuguna, et al.
Plos One|December 3, 2010
The ERAD inhibitor Eeyarestatin I is a bifunctional compound with a membrane-binding domain and a p97/VCP inhibitory groupQiuyan Wang, Bidhan A Shinkre, Jin-gu Lee, et al.
JAMA Dermatology|March 17, 2016
Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic LeukemiaCarole Bitar, Mohammed Z H Farooqui, Janet Valdez, et al.
British Journal of Haematology|December 5, 2021
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trialsJohn N Allan, Tait Shanafelt, Adrian Wiestner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2012
ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stressColby M Chapman, Xiameng Sun, Mark Roschewski, et al.
Oncotarget|February 26, 2015
Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphomaVioletta V Leshchenko, Pei-Yu Kuo, Zewei Jiang, et al.
Pageof 19

Showing results (71-80 of 182) with videos related to

Sort By:
Pageof 19
Blood|March 25, 2014
Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLLSarah E M Herman, Rashida Z Mustafa, Jennifer A Gyamfi, et al.
Blood|December 2, 2004
Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent mannerRuth Seggewiss, Karin Loré, Elisabeth Greiner, et al.
Haematologica|February 4, 2017
Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemiaMika Shapiro, Yair Herishanu, Ben-Zion Katz, et al.
Cancer Research|October 26, 2014
Harnessing the fcμ receptor for potent and selective cytotoxic therapy of chronic lymphocytic leukemiaBérengère Vire, Martin Skarzynski, Joshua D Thomas, et al.
Leukemia & Lymphoma|June 9, 2011
Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1Yair Herishanu, Federica Gibellini, Ndegwa Njuguna, et al.
Plos One|December 3, 2010
The ERAD inhibitor Eeyarestatin I is a bifunctional compound with a membrane-binding domain and a p97/VCP inhibitory groupQiuyan Wang, Bidhan A Shinkre, Jin-gu Lee, et al.
JAMA Dermatology|March 17, 2016
Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic LeukemiaCarole Bitar, Mohammed Z H Farooqui, Janet Valdez, et al.
British Journal of Haematology|December 5, 2021
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trialsJohn N Allan, Tait Shanafelt, Adrian Wiestner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2012
ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stressColby M Chapman, Xiameng Sun, Mark Roschewski, et al.
Oncotarget|February 26, 2015
Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphomaVioletta V Leshchenko, Pei-Yu Kuo, Zewei Jiang, et al.
Pageof 19